Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KATZ, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KATZ, H. L.
(Chest. 1957;32:626-635.)
© 1957 American College of Chest Physicians

Prolonged Blood Levels with Sustained Action PAS

HARRY L. KATZ M.D., F.C.C.P.1

1 The Chest Section, Medical Service, Veterans Administration Hospital.

1. Sustained action PAS tablets (Parasal-S.A., 1.0 Gm., sodium free) offer a convenient means of PAS therapy with a high degree of toleration. Acceptance of this drug was excellent since a four gram dose of free PAS consisted of only four tablets. Patients who manifested symptoms of gastrointestinal irritation due to standard PAS preparations tolerated sustained action PAS tablets with minimal, if any, gastrointestinal side-effects.

2. Sustained action PAS tablets, in dosage of four grams (4 tablets) three times daily at six hour intervals, generally provided sustained therapeutically effective PAS blood concentrations for 24 hours. No other PAS preparation, in equivalent dosage, studied to date, produced such sustained 24 hour PAS blood levels.

3. The clinical implications and probable advantages inherent in the use of sustained action PAS, administered concurrently with isoniazid or streptomycin, are believed to be as follows: a) sustained PAS concentrations within the tuberculous lesions; b) sustained and increased biologically active isoniazid levels in the blood and diseased tissues; c) greater inhibition or delay in the emergence of isoniazid or streptomycin resistant bacilli. Sustained action PAS may, therefore, serve to potentiate the therapeutic efficacy of antituberculous combined chemotherapy regimens.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1957 by the American College of Chest Physicians.